TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07285785: Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Sponsor: Bausch Health Americas, Inc. · Phase: PHASE4 · Area: INFECTIOUS_VACCINE · Target Enrollment: 54 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,034,880

Rescue Site Savings

+$682,080

Unlock Full NCT07285785 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07285785 Rescue Dossier →